Genitourinary Cancers

The FDA has granted a priority review to pembrolizumab as a treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma, according to Merck, the developer of the PD-1 inhibitor.

Chung-Han (Joe) Lee, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy in the treatment landscape of renal cell carcinoma.

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy, based on findings from the phase II CheckMate-275 study.

Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, 2016 Giant of Cancer Care in Genitourinary Cancer, discusses the data seen thus far with nivolumab plus ipilimumab in the treatment of patients with renal cell carcinoma.

The FDA has granted an accelerated approval to nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy, based on findings from a phase II CheckMate-275 study.

Treatment with the PD-1 inhibitor pembrolizumab significantly prolonged overall survival over investigators’ choice of chemotherapy in patients with recurrent advanced urothelial carcinoma, according to results reported at the 19th European Cancer Congress.

Jun Gong, MD, fellow, City of Hope, discusses adverse events (AEs) associated with TKI/VEGF-directed therapy for patients with metastatic renal cell carcinoma (RCC).

Raoul Concepcion, MD, director of the Comprehensive Prostate Center, discusses the impending transition to a value-based model in urology.

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses immune checkpoint inhibitors that are currently being evaluated for the treatment of patients with bladder cancer.

Tian Zhang, MD, a medical instructor in the Department of Medicine, Duke University School of Medicine, discusses some of the challenges associated with administering vaccines to patients with renal cell carcinoma.

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the potential of immunotherapy agents in the treatment of patients with bladder cancer.

Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential that immunotherapy has in the frontline setting for patients with bladder cancer.

Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, 2016 Giant of Cancer Care in Genitourinary Cancer, discusses the explosion of immunotherapy in the landscape of renal cell carcinoma (RCC).

Neeraj Agarwal, MD, discusses a trend of underreporting and underemphasizing toxicities associated with PD-1 inhibitors in the treatment of patients with renal cell carcinoma.

Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the potential with immunotherapy in the preoperative setting for patients with renal cell carcinoma.

Elizabeth Plimack, MD, discusses updated data from the pivotal CheckMate-025 trial, which compared the use of nivolumab with everolimus in the treatment of patients with metastatic renal cell carcinoma.

Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology and associate director of academic program development in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses tyrosine kinase inhibitors that he uses to treat patients with renal cell carcinoma.

Tian Zhang, MD, discusses the development of vaccines to treat patients with renal cell carcinoma.

David F. McDermott, MD, discusses ongoing efforts to improve outcomes in advanced renal cell carcinoma through combination anti–VEGF/PD-1 regimens.

The tyrosine kinase inhibitor axitinib has been standard in the management of advanced renal cell carcinoma for about 5 years now, but the emergence of new agents has made some members of the oncology community concerned that its significance will be overlooked in favor of more recently approved treatments.

Neeraj Agarwal, associate professor in the Division of Oncology, Department of Medicine, director of the Genitourinary Medical Oncology Program, Huntsman Cancer Institute at the University of Utah, discusses some of the adverse events (AEs) associated with checkpoint inhibitors for the treatment of patients with renal cell carcinoma (RCC).

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses major targeted agents currently being studied in the treatment of patients with bladder cancer.

Robert J. Motzer, MD, attending physician, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, and professor of Medicine, Weill Medical College, Cornell University, discusses the FDA approval of nivolumab (Opdivo) versus everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC).

Guru Sonpavde, MD, discusses challenges with sequencing in advanced renal cell carcinoma and his vision for the field going forward.

David F. McDermott, MD, Director of Biologic Therapy and Cutaneous Oncology Programs, Hematology and Oncology at the Beth Israel Deaconess Medical Center, discusses the combination of VEGF plus PD-1 in renal cell carcinoma (RCC).